Kilitch Ebit vs Cost Of Revenue Analysis

KILITCH Stock

315.60 4.95 1.59%

Kilitch Drugs financial indicator trend analysis is infinitely more than just investigating Kilitch Drugs Limited recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kilitch Drugs Limited is a good investment. Please check the relationship between Kilitch Drugs Ebit and its Cost Of Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Ebit vs Cost Of Revenue

Ebit vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kilitch Drugs Limited Ebit account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Kilitch Drugs' Ebit and Cost Of Revenue is 0.61. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Kilitch Drugs Limited, assuming nothing else is changed. The correlation between historical values of Kilitch Drugs' Ebit and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Kilitch Drugs Limited are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebit i.e., Kilitch Drugs' Ebit and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Ebit

Cost Of Revenue

Cost of Revenue is found on Kilitch Drugs Limited income statement and represents the costs associated with goods and services Kilitch Drugs provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Kilitch Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kilitch Drugs Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kilitch Drugs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

As of now, Kilitch Drugs' Tax Provision is increasing as compared to previous years. The Kilitch Drugs' current Issuance Of Capital Stock is estimated to increase to about 40.5 M, while Selling General Administrative is projected to decrease to under 25 M.

	2021	2022	2023	2024 (projected)
Gross Profit	488.0M	648.4M	620.5M	310.3M
Total Revenue	1.1B	1.4B	1.5B	889.7M

Gross Profit Total Revenue

Kilitch Drugs fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Current Deferred Revenue	Retained Earnings	Short Term Investments	Intangible Assets
Total Assets		0.6	-0.6	0.81	0.83	0.53	0.19	0.36	0.47	-0.17	0.42	0.61	0.2	-0.49	0.31	-0.13	0.58	0.69	0.76	0.43	0.77	0.74	-0.18	0.61	-0.14	0.02
Short Long Term Debt Total	0.6		0.06	0.71	0.21	0.71	0.6	0.1	0.46	-0.53	-0.05	0.75	-0.05	0.19	0.72	-0.25	0.32	0.73	0.32	0.7	0.25	0.55	0.2	0.58	0.09	-0.09
Other Current Liab	-0.6	0.06		-0.11	-0.87	0.17	0.29	-0.26	-0.2	-0.15	-0.43	-0.23	-0.21	0.98	0.22	-0.15	-0.52	0.08	-0.52	-0.09	-0.9	-0.19	0.61	-0.1	0.54	-0.09
Total Current Liabilities	0.81	0.71	-0.11		0.35	0.77	0.44	0.18	0.4	-0.2	0.31	0.5	0.31	0.03	0.36	-0.19	0.26	0.98	0.6	0.3	0.33	0.82	0.32	0.47	0.26	-0.05
Total Stockholder Equity	0.83	0.21	-0.87	0.35		0.11	-0.14	0.4	0.36	-0.04	0.4	0.46	0.06	-0.84	0.09	-0.01	0.67	0.18	0.65	0.34	0.91	0.4	-0.58	0.49	-0.47	0.09
Property Plant And Equipment Net	0.53	0.71	0.17	0.77	0.11		0.56	0.04	0.72	-0.66	-0.24	0.25	-0.25	0.27	0.57	0.12	0.07	0.8	0.06	0.62	0.21	0.83	0.09	0.28	0.0	-0.1
Net Debt	0.19	0.6	0.29	0.44	-0.14	0.56		-0.69	0.41	-0.46	-0.34	0.29	-0.06	0.37	0.56	0.09	0.17	0.5	-0.09	0.39	-0.02	0.31	0.29	0.07	0.2	-0.02
Cash	0.36	0.1	-0.26	0.18	0.4	0.04	-0.69		-0.06	0.1	0.39	0.23	0.05	-0.25	-0.01	-0.32	0.1	0.13	0.44	0.09	0.24	0.18	-0.14	0.48	-0.12	-0.04
Non Current Assets Total	0.47	0.46	-0.2	0.4	0.36	0.72	0.41	-0.06		-0.85	-0.56	0.23	-0.48	-0.17	0.42	0.44	0.34	0.35	-0.22	0.72	0.51	0.63	-0.42	0.08	-0.65	0.13
Non Currrent Assets Other	-0.17	-0.53	-0.15	-0.2	-0.04	-0.66	-0.46	0.1	-0.85		0.79	-0.26	0.68	-0.16	-0.57	-0.38	-0.11	-0.22	0.45	-0.82	-0.22	-0.43	0.31	-0.01	0.55	-0.13
Cash And Short Term Investments	0.42	-0.05	-0.43	0.31	0.4	-0.24	-0.34	0.39	-0.56	0.79		0.14	0.72	-0.37	-0.27	-0.46	0.15	0.23	0.88	-0.45	0.23	0.04	0.22	0.35	0.48	-0.16
Net Receivables	0.61	0.75	-0.23	0.5	0.46	0.25	0.29	0.23	0.23	-0.26	0.14		-0.04	-0.14	0.39	-0.47	0.38	0.45	0.51	0.6	0.35	0.41	-0.06	0.69	-0.05	0.01
Common Stock Shares Outstanding	0.2	-0.05	-0.21	0.31	0.06	-0.25	-0.06	0.05	-0.48	0.68	0.72	-0.04		-0.12	-0.21	-0.24	0.15	0.28	0.57	-0.69	0.0	-0.17	0.62	0.0	0.53	-0.1
Non Current Liabilities Total	-0.49	0.19	0.98	0.03	-0.84	0.27	0.37	-0.25	-0.17	-0.16	-0.37	-0.14	-0.12		0.29	-0.2	-0.48	0.23	-0.42	-0.06	-0.86	-0.1	0.7	-0.03	0.6	-0.12
Inventory	0.31	0.72	0.22	0.36	0.09	0.57	0.56	-0.01	0.42	-0.57	-0.27	0.39	-0.21	0.29		-0.02	0.4	0.41	0.02	0.58	0.1	0.2	0.13	0.42	0.01	-0.27
Other Current Assets	-0.13	-0.25	-0.15	-0.19	-0.01	0.12	0.09	-0.32	0.44	-0.38	-0.46	-0.47	-0.24	-0.2	-0.02		-0.02	-0.22	-0.48	0.07	0.25	0.01	-0.33	-0.68	-0.53	0.06
Other Stockholder Equity	0.58	0.32	-0.52	0.26	0.67	0.07	0.17	0.1	0.34	-0.11	0.15	0.38	0.15	-0.48	0.4	-0.02		0.16	0.39	0.26	0.55	0.11	-0.24	0.51	-0.3	0.36
Total Liab	0.69	0.73	0.08	0.98	0.18	0.8	0.5	0.13	0.35	-0.22	0.23	0.45	0.28	0.23	0.41	-0.22	0.16		0.5	0.27	0.15	0.78	0.45	0.45	0.38	-0.07
Total Current Assets	0.76	0.32	-0.52	0.6	0.65	0.06	-0.09	0.44	-0.22	0.45	0.88	0.51	0.57	-0.42	0.02	-0.48	0.39	0.5		-0.06	0.47	0.34	0.11	0.61	0.32	-0.08
Short Term Debt	0.43	0.7	-0.09	0.3	0.34	0.62	0.39	0.09	0.72	-0.82	-0.45	0.6	-0.69	-0.06	0.58	0.07	0.26	0.27	-0.06		0.43	0.55	-0.48	0.41	-0.48	0.04
Common Stock	0.77	0.25	-0.9	0.33	0.91	0.21	-0.02	0.24	0.51	-0.22	0.23	0.35	0.0	-0.86	0.1	0.25	0.55	0.15	0.47	0.43		0.43	-0.63	0.21	-0.61	0.04
Accounts Payable	0.74	0.55	-0.19	0.82	0.4	0.83	0.31	0.18	0.63	-0.43	0.04	0.41	-0.17	-0.1	0.2	0.01	0.11	0.78	0.34	0.55	0.43		-0.14	0.34	-0.1	0.04
Current Deferred Revenue	-0.18	0.2	0.61	0.32	-0.58	0.09	0.29	-0.14	-0.42	0.31	0.22	-0.06	0.62	0.7	0.13	-0.33	-0.24	0.45	0.11	-0.48	-0.63	-0.14		0.01	0.84	-0.16
Retained Earnings	0.61	0.58	-0.1	0.47	0.49	0.28	0.07	0.48	0.08	-0.01	0.35	0.69	0.0	-0.03	0.42	-0.68	0.51	0.45	0.61	0.41	0.21	0.34	0.01		0.18	0.03
Short Term Investments	-0.14	0.09	0.54	0.26	-0.47	0.0	0.2	-0.12	-0.65	0.55	0.48	-0.05	0.53	0.6	0.01	-0.53	-0.3	0.38	0.32	-0.48	-0.61	-0.1	0.84	0.18		-0.23
Intangible Assets	0.02	-0.09	-0.09	-0.05	0.09	-0.1	-0.02	-0.04	0.13	-0.13	-0.16	0.01	-0.1	-0.12	-0.27	0.06	0.36	-0.07	-0.08	0.04	0.04	0.04	-0.16	0.03	-0.23

Click cells to compare fundamentals

Kilitch Drugs Account Relationship Matchups

Kilitch Drugs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4B	2.0B	2.1B	2.2B	2.4B	1.7B
Short Long Term Debt Total	126.1M	148.0M	204.3M	221.9M	316.5M	332.3M
Other Current Liab	21.0M	22.3M	15.8M	17.7M	16.8M	15.9M
Total Current Liabilities	219.7M	733.2M	692.8M	688.7M	642.2M	369.3M
Total Stockholder Equity	1.2B	1.3B	1.4B	1.5B	1.8B	1.2B
Property Plant And Equipment Net	383.3M	733.8M	537.5M	473.6M	481.2M	293.0M
Net Debt	98.5M	23.6M	104.2M	23.5M	127.4M	68.2M
Cash	27.6M	124.5M	100.1M	198.5M	189.1M	99.1M
Non Current Assets Total	870.5M	1.2B	957.4M	931.2M	940.7M	749.4M
Non Currrent Assets Other	3.6M	4.4M	(68.8M)	6.2M	7.2M	6.8M
Cash And Short Term Investments	305.7M	488.5M	572.4M	592.0M	690.2M	474.6M
Net Receivables	(341K)	(522K)	414.3M	542.9M	632.6M	664.2M
Common Stock Shares Outstanding	15.4M	15.5M	15.6M	15.6M	15.9M	15.4M
Liabilities And Stockholders Equity	1.4B	2.0B	2.1B	2.2B	2.4B	1.7B
Non Current Liabilities Total	3.9M	3.8M	2.8M	683K	1.7M	1.6M
Inventory	55.6M	35.9M	52.9M	20.4M	93.1M	49.7M
Other Current Assets	196.6M	279.3M	20.0M	28.8M	43.5M	41.3M
Total Liab	223.6M	737.0M	695.5M	689.4M	643.9M	357.3M
Total Current Assets	557.9M	803.6M	1.1B	1.3B	1.5B	916.0M
Accumulated Other Comprehensive Income	(195.5M)	209.1M	254.1M	274.8M	287.1M	301.5M
Short Term Debt	126.1M	148.0M	204.3M	221.9M	316.5M	332.3M
Common Stock	153.6M	154.3M	154.9M	155.8M	160.8M	150.7M
Accounts Payable	71.0M	536.5M	428.7M	408.7M	255.9M	177.6M
Current Deferred Revenue	16.9M	42.9M	58.9M	55.9M	53.1M	59.2M
Retained Earnings	481.4M	518.2M	591.8M	696.3M	842.3M	624.5M
Short Term Investments	278.1M	364.0M	472.3M	393.5M	501.1M	378.1M
Intangible Assets	502K	1.5M	2.3M	204.8M	4.4M	4.2M
Other Liab	3.9M	3.8M	2.8M	683K	614.7K	584.0K
Net Tangible Assets	954.5M	1.1B	1.2B	1.3B	1.5B	1.1B
Other Assets	13.3M	17.2M	19.7M	19.8M	1.0	0.95
Property Plant Equipment	383.3M	733.8M	464.0M	473.6M	544.6M	309.3M
Short Long Term Debt	126.1M	148.0M	204.3M	221.9M	316.5M	332.3M
Good Will	227.5M	219.1M	210.6M	202.2M	193.8M	189.4M
Net Invested Capital	1.3B	1.4B	1.6B	1.7B	2.1B	1.7B
Net Working Capital	338.1M	70.5M	448.3M	575.3M	817.8M	499.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Kilitch Stock

Balance Sheet is a snapshot of the financial position of Kilitch Drugs Limited at a specified time, usually calculated after every quarter, six months, or one year. Kilitch Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kilitch Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kilitch currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kilitch Ebit vs Cost Of Revenue Analysis

Ebit vs Cost Of Revenue

Ebit vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebit

Cost Of Revenue

Kilitch Drugs fundamental ratios Correlations

Kilitch Drugs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kilitch Drugs fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Kilitch Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 0.98	Other Current Liab
Total Liab	+ 0.98	Total Current Liabilities
Common Stock	+ 0.91	Total Stockholder Equity
Total Current Assets	+ 0.88	Cash And Short Term Investments
Short Term Investments	+ 0.84	Current Deferred Revenue
Total Stockholder Equity	+ 0.83	Total Assets

Common Stock	- 0.9	Other Current Liab
Total Stockholder Equity	- 0.87	Other Current Liab
Common Stock	- 0.86	Non Current Liabilities Total
Non Currrent Assets Other	- 0.85	Non Current Assets Total
Non Current Liabilities Total	- 0.84	Total Stockholder Equity
Short Term Debt	- 0.82	Non Currrent Assets Other